Biovest set to unveil its personalized lymphoma vaccine

TAMPA, Fla. and MINNEAPOLIS — Biovest International Inc. announced March 17 that it will present information about its personalized cancer vaccine, BiovaxID, at the following upcoming conferences:

n World Vaccine Congress 2010, April 19-22 in Washington D.C.

n BIO International Convention, May 3-6 in Chicago

n and Active Immunotherapeutics Forum 2010, June 21-23 in Barcelona, Spain

At these events, Biovest plans to review positive Phase II and Phase III data for BiovaxID and discuss the potential market opportunity including regulatory and manufacturing strategies.

In addition, Biovest officials will attend the American Society of Oncology’s annual meeting June 4-8 in Chicago to meet with potential corporate partners, experts in lymphomas and patient advocacy groups.

Biovest International Inc. focuses personalized immunotherapies targeting life-threatening cancers of the blood system. Developed in collaboration with the National Cancer Institute, BiovaxID is a patient-specific, anti-lymphoma cancer vaccine intended to prolong survival in patients with indolent follicular non-Hodgkin’s lymphoma. BiovaxID has been granted orphan drug designation by both the U.S. Food and Drug Administration and the European EMEA.